308 related articles for article (PubMed ID: 29596725)
1. Antagonists in the medical management of opioid use disorders: Historical and existing treatment strategies.
Bisaga A; Mannelli P; Sullivan MA; Vosburg SK; Compton P; Woody GE; Kosten TR
Am J Addict; 2018 Apr; 27(3):177-187. PubMed ID: 29596725
[TBL] [Abstract][Full Text] [Related]
2. Review article: Effective management of opioid withdrawal symptoms: A gateway to opioid dependence treatment.
Kosten TR; Baxter LE
Am J Addict; 2019 Feb; 28(2):55-62. PubMed ID: 30701615
[TBL] [Abstract][Full Text] [Related]
3. Management of opioid withdrawal and initiation of medications for opioid use disorder in the hospital setting.
Carswell N; Angermaier G; Castaneda C; Delgado F
Hosp Pract (1995); 2022 Oct; 50(4):251-258. PubMed ID: 35837678
[TBL] [Abstract][Full Text] [Related]
4. Adjunctive memantine for opioid use disorder treatment: A systematic review.
Elias AM; Pepin MJ; Brown JN
J Subst Abuse Treat; 2019 Dec; 107():38-43. PubMed ID: 31757263
[TBL] [Abstract][Full Text] [Related]
5. Open label trial of lofexidine-assisted non-opioid induction onto naltrexone extended-release injection for opioid use disorder.
Mariani JJ; Basaraba C; Pavlicova M; Alschuler DM; Brooks DJ; Mahony AL; Brezing C; Naqvi NH; Levin FR
Am J Drug Alcohol Abuse; 2023 Sep; 49(5):618-629. PubMed ID: 37791817
[No Abstract] [Full Text] [Related]
6. Measurement-based care using DSM-5 for opioid use disorder: can we make opioid medication treatment more effective?
Marsden J; Tai B; Ali R; Hu L; Rush AJ; Volkow N
Addiction; 2019 Aug; 114(8):1346-1353. PubMed ID: 30614096
[TBL] [Abstract][Full Text] [Related]
7. Opioid withdrawal symptoms, a consequence of chronic opioid use and opioid use disorder: Current understanding and approaches to management.
Pergolizzi JV; Raffa RB; Rosenblatt MH
J Clin Pharm Ther; 2020 Oct; 45(5):892-903. PubMed ID: 31986228
[TBL] [Abstract][Full Text] [Related]
8. A novel non-opioid protocol for medically supervised opioid withdrawal and transition to antagonist treatment.
Rudolf G; Walsh J; Plawman A; Gianutsos P; Alto W; Mancl L; Rudolf V
Am J Drug Alcohol Abuse; 2018; 44(3):302-309. PubMed ID: 28795846
[TBL] [Abstract][Full Text] [Related]
9. Non-Opioid Treatments for Opioid Use Disorder: Rationales and Data to Date.
Chalhoub RM; Kalivas PW
Drugs; 2020 Oct; 80(15):1509-1524. PubMed ID: 32776315
[TBL] [Abstract][Full Text] [Related]
10. Patterns of withdrawal in patients with opioid use disorder (OUD) transitioning from untreated OUD or buprenorphine treatment to extended-release naltrexone.
Mannelli P; Douaihy AB; Zavod A; Legedza A; Akerman SC; Sullivan MA
Am J Drug Alcohol Abuse; 2021 Nov; 47(6):753-759. PubMed ID: 34752714
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.
Dunn KE; Tompkins DA; Bigelow GE; Strain EC
JAMA Psychiatry; 2017 Sep; 74(9):885-893. PubMed ID: 28700791
[TBL] [Abstract][Full Text] [Related]
12. Buprenorphine therapy in the setting of induced opioid withdrawal from oral naltrexone: a case report.
Szczesniak LM; Calleo VJ; Sullivan RW
Harm Reduct J; 2020 Oct; 17(1):71. PubMed ID: 33028340
[TBL] [Abstract][Full Text] [Related]
13. Extended-release naltrexone for youth with opioid use disorder.
Mitchell SG; Monico LB; Gryczynski J; Fishman MJ; O'Grady KE; Schwartz RP
J Subst Abuse Treat; 2021 Nov; 130():108407. PubMed ID: 34118699
[TBL] [Abstract][Full Text] [Related]
14. Withdrawal severity and early response to treatment in the outpatient transition from opioid use to extended release naltrexone.
Mannelli P; Swartz M; Wu LT
Am J Addict; 2018 Sep; 27(6):471-476. PubMed ID: 30028058
[TBL] [Abstract][Full Text] [Related]
15. Test of a workforce development intervention to expand opioid use disorder treatment pharmacotherapy prescribers: protocol for a cluster randomized trial.
Molfenter T; Knudsen HK; Brown R; Jacobson N; Horst J; Van Etten M; Kim JS; Haram E; Collier E; Starr S; Toy A; Madden L
Implement Sci; 2017 Nov; 12(1):135. PubMed ID: 29141653
[TBL] [Abstract][Full Text] [Related]
16. Treatment of opioid use disorder in primary care.
Buresh M; Stern R; Rastegar D
BMJ; 2021 May; 373():n784. PubMed ID: 34011512
[TBL] [Abstract][Full Text] [Related]
17. Clinical Management of Opioid Withdrawal.
Torres-Lockhart KE; Lu TY; Weimer MB; Stein MR; Cunningham CO
Addiction; 2022 Sep; 117(9):2540-2550. PubMed ID: 35112746
[TBL] [Abstract][Full Text] [Related]
18. Lorcaserin treatment for extended-release naltrexone induction and retention for opioid use disorder individuals: A pilot, placebo-controlled randomized trial.
Levin FR; Mariani JJ; Pavlicova M; Choi CJ; Basaraba C; Mahony AL; Brooks DJ; Naqvi N; Bisaga A
Drug Alcohol Depend; 2021 Feb; 219():108482. PubMed ID: 33418204
[TBL] [Abstract][Full Text] [Related]
19. Opioid antagonists with minimal sedation for opioid withdrawal.
Gowing L; Ali R; White JM
Cochrane Database Syst Rev; 2017 May; 5(5):CD002021. PubMed ID: 28553701
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
